¹ÎÈ«±â ¸íÀÇ

¹ÎÈ«±â ¸íÀÇ

  • ¼Ò ¼Ó
    °Ç±¹´ëÇб³º´¿ø ·ù¸¶Æ¼½º³»°ú
  • Áø·á°ú
    ·ù¸¶Æ¼½º³»°ú
  • Àü¹®ºÐ¾ß
    Èñ±ÍÁúȯŬ¸®´Ð, ·ù¸¶Æ¼½º°üÀý¿°, ·çǪ½º, °­Á÷¼ºÃ´Ãß¿°, °Ç¼±°üÀý¿°, ¼î±×·»ÁõÈıº, ÅðÇ༺°üÀý¿°, º£Ã¼Æ®º´, Ç÷°ü¿°

¸íÀÇÇÁ·ÎÇÊ ¸íÀÇ ÇÁ·ÎÇÊ

ÇзÂ

  • °¡Å縯´ë ÀÇ´ë Çлç
  • °¡Å縯´ë ÀÇ´ë ¹Ú»ç

ÁÖ¿ä°æ·Â

¼ö»ó³»¿ª

  • ´ëÇÑ·ù¸¶Æ¼½ºÇÐȸ ÀþÀº¿¬±¸ÀÚ»ó (2021)

ÁýÇÊÀú¼­

ÃÑ 0°Ç

ÁÖ¿ä³í¹®

ÃÑ 7°Ç
Á¦ ¸ñ Remdesivir alleviates joint damage in collagen-induced arthritis and inhibits inflammatory cell death of RA synovial fibroblasts.
¹ßÇ¥³âµµ 2025
¹ßÇ¥Áö
Á¦ ¸ñ Are ultrasound salivary parenchymal lesions more severe in primary Sjögren patients with a longer disease duration? A cross-sectional study.
¹ßÇ¥³âµµ 2025
¹ßÇ¥Áö 2025
Á¦ ¸ñ Impact of csDMARDs vs. b/tsDMARDs on the Prognosis of Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Multicenter, Retrospective Study.
¹ßÇ¥³âµµ
¹ßÇ¥Áö
Á¦ ¸ñ Human nasal turbinate stem cells with specific gene signatures (HAS2, CXCL1, KRTAP1-5, GSTT2B, and C4B) attenuate rheumatoid arthritis.
¹ßÇ¥³âµµ 2025
¹ßÇ¥Áö
Á¦ ¸ñ Suppressing anti-citrullinated protein antibody-induced osteoclastogenesis in rheumatoid arthritis using anti-CD64 and PAD-2 inhibitors.
¹ßÇ¥³âµµ 2025
¹ßÇ¥Áö
Á¦ ¸ñ Interleukin-18 binding protein regulates mast cell activation and mast cell induced osteoclastogenesis of rheumatoid arthritis.
¹ßÇ¥³âµµ 2025
¹ßÇ¥Áö
Á¦ ¸ñ Interleukin-18 binding protein regulates mast cell activation and mast cell induced osteoclastogenesis of rheumatoid arthritis.
¹ßÇ¥³âµµ 2024
¹ßÇ¥Áö

¸íÀÇqna ¸íÀÇ QnA

°¡Àå °ü½É ÀÖ´Â ºÐ¾ß¿Í ¾÷ÀûÀÌ ÀÖ´Ù¸é ¾Ë·ÁÁÖ¼¼¿ä
ȯÀÚ Áø·á¿¡ ÀÖ¾î °¡Àå Áß¿äÇÏ°Ô »ý°¢ÇÏ´Â °¡Ä¡´Â?
ȯÀڵ鿡°Ô ÀüÇÏ°í ½ÍÀº ¸»¾¸

¸íÀÇqna ¸íÀÇ ¼Ò¼Óº´¿ø

°Ç±¹´ëÇб³º´¿ø

»ó±ÞÁ¾ÇÕº´¿ø
ÀüÈ­ ¾ÆÀÌÄÜ ´ëÇ¥¹øÈ£
1588-1533
À¥»çÀÌÆ® ¾ÆÀÌÄÜȨÆäÀÌÁö
°Ç±¹´ëÇб³º´¿ø À̹ÌÁö

ÁÖ¿ä½Ã¼³

ÀÀ±Þ½Ç ÀÀ±Þ½Ç
Ŭ¸®´Ð Ŭ¸®´Ð
Á¾ÇÕ°ËÁø¼¾ÅÍ Á¾ÇÕ°ËÁø¼¾ÅÍ
¾Ï¼¾ÅÍ ¾Ï¼¾ÅÍ
ÁÖÂ÷½Ã¼³ ÁÖÂ÷½Ã¼³

°Ç±¹´ëÇб³º´¿øÀº »óÇã À¯¼®Ã¢ ¼±»ý²²¼­ ÀÏÁ¦ °­Á¡±âÀÎ 1931³â ¹ÎÁ·ÁöµµÀÚµé°ú ¶æÀ» ¸ð¾Æ ±¸·áÁ¦¹Î(Ï­Öûð­ÚÅ)°ú Àμúº¸±¹(ìÒâúÜÃÏÐ)ÀÇ Å« ¶æÀ» ´ã¾Æ ¼³¸³ÇÑ ¡®»çȸ¿µ Á߾ӽǺñÁø·á¿ø¡¯¿¡ »Ñ¸®¸¦ µÎ°í ÀÖ´Ù. 2002³â °Ç±¹´ëÇб³ ¼­¿ïÄ·ÆÛ½º ³²´Ü¿¡ º´¿ø °Ç¹°À» »õ·Î Áþ±â ½ÃÀÛÇØ 2005³â 8¿ù »õ·Ó°Ô žÀ¸¸ç ÁöÇÏ4Ãþ, Áö»ó 13Ãþ ¿¬¸éÀû 2¸¸ 6300¿©ÆòÀÇ »õ °Ç±¹´ëº´¿øÀº 33°³ÀÇ Áø·á°ú¿Í 784°³ÀÇ º´»ó, 9°³ÀÇ ÁßÁ¡¼¾ÅÍ¿Í 14°³ÀÇ Áø·á¼¾ÅÍ, ÇコÄɾÅ͸¦ °®Ãß°í 430¿©¸íÀÇ ÀÇ·áÁøÀÌ Áø·á¸¦ Çϰí ÀÖ´Ù. 2009³â °©»ó¼±¾Ï¼¾ÅÍ, ´ëÀå¾Ï¼¾ÅÍ, À¯¹æ¾Ï¼¾ÅÍ µî ¾Ï¼¾Å͸¦ °³¼³Çϰí, 2017³â 11¿ù¿¡´Â ÃÖ½ÅÇü ·Îº¿ ¸ðµ¨ÀÎ 4¼¼´ë ´ÙºóÄ¡Xi¸¦ µµÀÔ, ·Îº¿¼ö¼ú ¼¾ÅÍ °¡µ¿À» ½ÃÀÛÇß´Ù. °Ç±¹´ëº´¿øÀº ´ëÀå¾Ï, À¯¹æ¾Ï, Æó¾Ï, À§¾Ï, Ç÷¾×Åõ¼®, ¸¸¼ºÆó¼â¼ºÆóÁúȯ µî ÁßÁõÁúȯ ºÐ¾ß Æò°¡¿¡¼­ 1µî±ÞÀ» ±â·ÏÇϰí ÀÖÀ¸¸ç, °ñµçŸÀÓÀÌ Áß¿äÇÑ ½ÉÇ÷°üÁúȯ°ú ³úÇ÷°üÁúȯÀÇ ½Å¼ÓÁø·á½Ã½ºÅÛÀ» ¿î¿µÇÏ¸ç ±Þ¼º±â ³úÁ¹Áß ¹× °ü»óµ¿¸Æ¿ìȸ¼ú Æò°¡¿¡¼­µµ 1µî±ÞÀ» À̾°í ÀÖ´Ù. Áö³­ 2023³â¿¡´Â ÁßÁõÁúȯ Ä¡·á ¿ª·® °­È­¸¦ À§ÇØ ÁßȯÀÚ½Ç ¹× ¼ö¼ú½Ç Áõ¼³, ·Îº¿¼ö¼ú±â±â Ãß°¡ ¹× CTµî ½ÅÇüÀÇ·áÀåºñ µîÀ» µµÀÔÇß´Ù. À̾î 2024³â¿¡´Â ȯÀÚµéÀÇ ÄèÀûÇÑ È¯°æÀ» À§ÇØ º´µ¿ ȯ°æÀ» °³¼±Çϰí, 2025³â¿¡´Â ¿Ü·¡¼¾ÅÍ ÁõÃàÀ» ¾ÕµÎ°í ÀÖ´Ù.

¼­¿ïƯº°½Ã ±¤Áø±¸ ´Éµ¿·Î 120-1(È­¾çµ¿) °Ç±¹´ëÇб³º´¿ø

Ȩ
³»°¡ ¾Ë°íÀÖ´Â ¸íÀǸ¦ ÃßÃµÇØÁÖ¼¼¿ä